In its third precedential patent opinion this week, the U.S. Court of Appeals for the Federal Circuit (CAFC) earlier today upheld a Patent Trial and Appeal Board (PTAB) decision finding that Mylan Pharmaceuticals, Inc. failed to show that certain claims of Merck Sharp & Dohme Corp.’s patent for a Type 2 Diabetes treatment were anticipated or would have been obvious over the cited prior art. Judge Lourie authored the opinion.
Recent Posts
- C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents
- Winning Strategies at the PTAB, Part I: Bring Your Game
- En Banc CAFC Overrules Design Patent Obviousness Test in Light of KSR
- CAFC Says IPRs are Voluntary, Fees Not Recoverable Under ‘Exceptionality’ Rule
- Why are the FDA and USPTO Ignoring Requests for Info on I-MAK?